Drug intelligence / Profile preview

ABS-003

Development stage: Preclinical
Lead developer: Alpha Biomedical
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ABS-003 is an investigational natural killer (NK) cell therapy currently in preclinical development by Alpha Biomedical. Designed for the treatment of breast cancer, the therapy leverages the innate immune system's ability to identify and destroy malignant cells. NK cells are cytotoxic lymphocytes that can induce apoptosis in tumor cells through the release of perforin and granzymes or via death receptor-mediated pathways. As an adoptive cell therapy, ABS-003 aims to provide a potent immune response against solid tumors in the breast.

Beyond the preview

Go deeper on ABS-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABS-003.

Explore the full profile